Last reviewed · How we verify

NCT06808841: Sipwlefsmdfs

Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study

Not yet recruiting NA Last updated 5 February 2025
What this trial tests

NA trial testing Sufentanil injection in Myocardial Injury in 160 participants. Not yet recruiting.

Timeline
5 February 2025
Primary endpoint
10 May 2025
10 May 2025

Quick facts

Lead sponsorSecond Hospital of Shanxi Medical University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment160
Start date5 February 2025
Primary completion10 May 2025
Estimated completion10 May 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Hospital of Shanxi Medical University

Who can join

Adults 18 to 65, any sex, with Myocardial Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To analyze the association of different doses of opioids on myocardial injury/protection through BMP-6/SMAD pathway. 2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow. 3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sufentanil injection

Trials testing the same drug.

Other recruiting trials for Myocardial Injury

Currently open trials in the same condition.

Other Second Hospital of Shanxi Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06808841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing